These results indicate that the NFL-TBS.40-63 peptide represents a promising therapeutic drug for glioblastoma treatment by targeting and killing both glioblastoma cells and BTICs to prevent recurrence.
Either suppressing miR-381 or enforcing NEFL expression dramatically sensitized glioblastoma cells to temozolomide (TMZ), a promising chemotherapeutic agent for treating GBMs.
We previously reported that a 24 amino acid peptide (NFL-TBS.40-63) corresponding to the tubulin-binding site located on the light neurofilament subunit, selectively enters in glioblastoma cells where it disrupts their microtubule network and inhibits their proliferation.